472 related articles for article (PubMed ID: 31587590)
21. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
22. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
Parikh M; Lara PN
Annu Rev Med; 2018 Jan; 69():209-221. PubMed ID: 29144835
[TBL] [Abstract][Full Text] [Related]
23. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Albiges L; Powles T; Staehler M; Bensalah K; Giles RH; Hora M; Kuczyk MA; Lam TB; Ljungberg B; Marconi L; Merseburger AS; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Bex A
Eur Urol; 2019 Aug; 76(2):151-156. PubMed ID: 31151678
[TBL] [Abstract][Full Text] [Related]
24. A review of checkpoint inhibitors in the management of renal cell carcinoma.
Hanna KS
J Oncol Pharm Pract; 2020 Mar; 26(2):445-458. PubMed ID: 31631812
[TBL] [Abstract][Full Text] [Related]
25. Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.
Verbiest A; Renders I; Caruso S; Couchy G; Job S; Laenen A; Verkarre V; Rioux-Leclercq N; Schöffski P; Vano Y; Elaidi RT; Lerut E; Albersen M; Oudard S; Fridman WH; Sautès-Fridman C; Albigès L; Wozniak A; Zucman-Rossi J; Beuselinck B
Clin Genitourin Cancer; 2019 Oct; 17(5):e981-e994. PubMed ID: 31229459
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
27. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.
Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Ricci AD; Grilli G; Greco A; Montironi R; Ardizzoni A; Massari F
Immunotherapy; 2021 Jun; 13(9):783-793. PubMed ID: 33906376
[No Abstract] [Full Text] [Related]
29. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
Loo V; Salgia M; Bergerot P; Philip EJ; Pal SK
Target Oncol; 2019 Dec; 14(6):639-645. PubMed ID: 31595385
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
31. Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Gao X; McDermott DF
Cancer J; 2018; 24(4):171-179. PubMed ID: 30119080
[TBL] [Abstract][Full Text] [Related]
32. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.
Massari F; Mollica V; Rizzo A; Cosmai L; Rizzo M; Porta C
Expert Opin Drug Saf; 2020 Oct; 19(10):1329-1338. PubMed ID: 32799582
[TBL] [Abstract][Full Text] [Related]
33. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
34. Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy.
Leslie I; Boos LA; Larkin J; Pickering L
Expert Rev Anticancer Ther; 2020 May; 20(5):343-354. PubMed ID: 32293937
[No Abstract] [Full Text] [Related]
35. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
36. A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint.
Hizal M; Sendur MAN; Bilgin B; Akinci MB; Sener Dede D; Yalcin B
Curr Med Res Opin; 2020 Apr; 36(4):625-635. PubMed ID: 31942809
[No Abstract] [Full Text] [Related]
37. Systematic review on the efficacy and safety of immune checkpoint inhibition in renal cell carcinoma.
Lyu C; Li W; Liu S; Gao S; Zhang H; Hao L; Yu H; Wei W; Song J; Yang Y; Wang C; Zhang Z; Wang N
Future Oncol; 2018 Sep; 14(21):2207-2221. PubMed ID: 29726696
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy in metastatic renal cell carcinoma: Back to the future?
Cerbone L; Cattrini C; Vallome G; Latocca MM; Boccardo F; Zanardi E
Semin Oncol; 2020 Dec; 47(6):361-366. PubMed ID: 33168323
[TBL] [Abstract][Full Text] [Related]
39. Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer.
Shaw T; Lee H; Figlin R
Oncology (Williston Park); 2021 Jun; 35(6):306-310. PubMed ID: 34139792
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
